Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study
, , , , , , oraz | 14 sie 2022
O artykule
Article Category: research article
Data publikacji: 14 sie 2022
Zakres stron: 371 - 379
Otrzymano: 31 sty 2022
Przyjęty: 07 kwi 2022
DOI: https://doi.org/10.2478/raon-2022-0025
© 2022 Nina Turnsek, Rok Devjak, Natalija Edelbaher, Ilonka Osrajnik, Mojca Unk, Dusanka Vidovic, Tina Jeric, Urska Janzic, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1
Figure 2
Figure 3
Clinical characteristics at the time of initial NSCLC diagnosis
| Characteristic | N = 120 n (%) |
|---|---|
| Smoking history | |
| Current smoker | 7 (6) |
| Former smoker | 33 (28) |
| Never smoker | 76 (63) |
| Unknown | 4 (3) |
| ECOG performance status | |
| 0 | 28 (23) |
| 1 | 62 (52) |
| 2 | 22 (18) |
| 3 | 6 (5) |
| 4 | 1 (1) |
| Unknown | 1 (1) |
| Stage at initial diagnosis | |
| Early stage (I-II) | 13 (11) |
| Limited regional (IIIA) | 4 (3) |
| Locally advanced (IIIB) | 0 |
| Metastatic (IV) | 103 (86) |
| Site of distant metastases | |
| Adrenal | 12 (10) |
| Bone | 54 (45) |
| Brain | 33 (28) |
| Liver | 19 (16) |
| Lung | 60 (50) |
| Lymph nodes | 60 (50) |
| Peritoneal | 2 (2) |
| Pleura | 38 (32) |
| Skin/soft tissue | 3 (3) |
| Other* | 10 (8) |